Bristol Myers Squibb (NYSE: BMY) announced positive topline results from its Phase 2 QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA